Zepbound Weight Loss Drug Is Now Available: Expert Answers for 10 Common Questions
Zepbound, a brand name for tirzepatide, was approved by the FDA for weight loss in November. It is a dual-agonist drug that activates GIP (glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, aiding in glucose management and helping patients feel fuller longer. In trials, patients lost an average of 26% body weight during 88 weeks, a higher percentage than patients taking semaglutide.
On November 8, 2023, Ozempic, Wegovy, and Mounjaro got company when the Food & Drug Administration approved Zepbound for individuals who are living with obesity or are overweight with at least one weight-related condition.
Source: Healthline
